Amadix

Amadix is a company focused on developing and commercializing innovative technologies for cancer diagnosis, specifically targeting unmet needs in oncology. Its flagship product, Colofast, is a non-invasive blood test designed for the early detection of colorectal cancer and advanced adenomas, addressing a significant health challenge due to the high mortality rate associated with colon cancer. The company emphasizes analytical validation and clinical utility, conducting international multicenter studies to support its products before global commercialization. Amadix is led by a team of experienced professionals with extensive backgrounds in oncology diagnostics, the pharmaceutical industry, and biotechnology. The management is complemented by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. By focusing on non-invasive early cancer detection, Amadix aims to offer safer alternatives to traditional invasive procedures, ultimately facilitating timely and effective treatment for patients.